Trial Profile
Luteinizing hormone-releasing hormone (LHRH) antagonists in advanced prostate cancer by assessing the parameters of electrical instability on the surface ECG and the global longitudinal strain on echocardiography
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2018
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 18 Sep 2018 New trial record
- 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology